Celldex Therapeutics Stock
Celldex Therapeutics Stock
Our community is currently high on Celldex Therapeutics with 9 Buy predictions and 3 Sell predictions.
With a target price of 39 € there is a hugely positive potential of 71.05% for Celldex Therapeutics compared to the current price of 22.8 €.
So far the community has only identified positive things for Celldex Therapeutics stock. The most positive votes were given for criterium "Worthwhile Investment for the next years".
Pros and Cons of Celldex Therapeutics in the next few years
Pros
?
C******** o* t** e**********
?
W********* I********* f** t** n*** y****
?
M***** P*******
Cons
?
B****
?
G***** c******* t* c**********
?
S********** s********
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Celldex Therapeutics vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Celldex Therapeutics | - | 3.636% | -9.524% | -10.938% | 3.636% | -43.312% | 67.155% |
| Vaxart Inc. | 0.000% | -2.857% | -3.478% | -69.558% | -2.857% | -70.531% | -94.963% |
| Larimar Therapeutics Inc. | -1.410% | -15.663% | -10.256% | -29.648% | -15.663% | -25.134% | -84.036% |
| aTyr Pharma Inc | -2.650% | -8.333% | -9.836% | -86.041% | -8.333% | -76.066% | -81.908% |
Comments
Celldex Therapeutics (NASDAQ:CLDX) had its price target raised by analysts at Barclays PLC from $21.00 to $24.00. They now have an "underweight" rating on the stock.
Show more
Ratings data for CLDX provided by MarketBeat
Celldex Therapeutics (NASDAQ:CLDX) had its price target lowered by analysts at Barclays PLC from $25.00 to $21.00. They now have an "underweight" rating on the stock.
Show more
Ratings data for CLDX provided by MarketBeat
Celldex Therapeutics (NASDAQ:CLDX) is now covered by analysts at Barclays PLC. They set an "underweight" rating and a $25.00 price target on the stock.
Show more
Ratings data for CLDX provided by MarketBeat